Managing External Health Information

As we move into a new era of health care with the increased exchange of medical records in order to provide better, more coordinated care, the question of what information received from outside an organization should be included in a medical record takes on new importance. What with health homes, personal health records, and health information exchanges, as well as increased involvement by patients using digital tools like smart watches and smart phone apps, there is a torrent of information being directed at medical records, and it is essential to understand what belongs there and what should be rejected, and how. This information may come in the form of unsolicited health information, for example, information that is volunteered by patients or by other health care providers, either at the time the patient arrives for treatment or thereafter, and in some cases even after the patient has been discharged.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

4 Creative Cost Strategies Changing Healthcare for Good

Paladina Health

Watch our webinar to gain “4 Creative Cost Strategies Changing Healthcare for Good.” You’ll hear healthcare experts from AON, Activate Healthcare, and Paladina Health share key insights on how to reduce employee healthcare expenses.
Watch Now

How Has COVID Permanently Changed Healthcare

COVID-19 transformed how we collectively delivered care in 2020. Not only are we seeing an upending of traditional health care settings, but patients increasingly expect to know the costs of their care ahead of time.
Watch Now

Immunotherapy Advances in Small Cell Lung Cancer

Cancerresearch

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.
Watch Now

Discover how targeted radiotherapy induced toxicity can be identified with imaging

This Pharma IQ webinar with AIQ explores how AI-assisted analysis of radiological scans enhances the understanding of treatment efficacy
Watch Now